BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 9554588)

  • 1. Phase II trial of combination chemotherapy with cisplatin, carboplatin and etoposide in stage IIIB and IV small-cell lung cancer. Fukuoka Lung Cancer Study Group.
    Nakanishi Y; Kawarada Y; Hirose N; Ninomiya K; Miyazaki M; Miyazaki N; Kurita Y; Kanegae H; Ohgushi O; Ogata K; Yamazaki H; Inutsuka S; Hara N
    Cancer Chemother Pharmacol; 1998; 41(6):453-6. PubMed ID: 9554588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
    J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
    Mavroudis D; Papadakis E; Veslemes M; Tsiafaki X; Stavrakakis J; Kouroussis C; Kakolyris S; Bania E; Jordanoglou J; Agelidou M; Vlachonicolis J; Georgoulias V;
    Ann Oncol; 2001 Apr; 12(4):463-70. PubMed ID: 11398877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
    Garst J; Herndon JE; Shafman T; Campagna L; Blackwell S; Padilla K; Bjurstrom T; Andrews C; Maravich-May D; Anderson E; Crawford J
    Clin Drug Investig; 2006; 26(5):257-66. PubMed ID: 17163259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group.
    Figlin RA; Crowley JJ; Jacobs EL; Muirhead M; Goodwin JW; Rinehart JJ; Livingston RB
    Cancer; 1996 Sep; 78(5):998-1003. PubMed ID: 8780537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
    Rajkumar SV; Frytak S; Rubin J; Camoriano JK; Fitch TR
    Am J Clin Oncol; 1997 Oct; 20(5):500-4. PubMed ID: 9345336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma.
    Hainsworth JD; Stroup SL; Greco FA
    Cancer; 1996 Jun; 77(12):2458-63. PubMed ID: 8640693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study.
    Skarlos DV; Samantas E; Kosmidis P; Fountzilas G; Angelidou M; Palamidas P; Mylonakis N; Provata A; Papadakis E; Klouvas G
    Ann Oncol; 1994 Sep; 5(7):601-7. PubMed ID: 7993835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
    Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
    Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin plus oral etoposide in the treatment of patients with advanced small cell lung cancer. Japan Clinical Oncology Group.
    Asamoto H; Kawahara M; Iwami F; Kuba M; Furuse K; Tamura T; Saijo N; Shimoyama M
    Jpn J Clin Oncol; 1998 Dec; 28(12):745-8. PubMed ID: 9879292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer.
    Comella P; Scoppa G; Daponte A; Musetta G; Anania C; Maiorino A; Curcio C; Casaretti R; Comella G
    Cancer; 1994 Oct; 74(7):1874-81. PubMed ID: 8082093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer.
    Fukuda M; Soda H; Soejima Y; Fukuda M; Kinoshita A; Takatani H; Kasai T; Nagashima S; Kawabata S; Doi S; Kohno S; Oka M
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):601-6. PubMed ID: 16463061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
    Hanna N; Bunn PA; Langer C; Einhorn L; Guthrie T; Beck T; Ansari R; Ellis P; Byrne M; Morrison M; Hariharan S; Wang B; Sandler A
    J Clin Oncol; 2006 May; 24(13):2038-43. PubMed ID: 16648503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer.
    Reck M; von Pawel J; Macha HN; Kaukel E; Deppermann KM; Bonnet R; Ulm K; Hessler S; Gatzemeier U
    J Natl Cancer Inst; 2003 Aug; 95(15):1118-27. PubMed ID: 12902441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer.
    Scagliotti GV; Ricardi U; Crinó L; Maranzano E; De Marinis F; Morandi MG; Meacci L; Marangolo M; Emiliani E; Rosti G; Figoli F; Bolzicco G; Masiero P; Gentile A; Tonato M
    Cancer Chemother Pharmacol; 1996; 38(6):561-5. PubMed ID: 8823499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
    Ihde DC; Mulshine JL; Kramer BS; Steinberg SM; Linnoila RI; Gazdar AF; Edison M; Phelps RM; Lesar M; Phares JC
    J Clin Oncol; 1994 Oct; 12(10):2022-34. PubMed ID: 7931470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: a University of Colorado Cancer Center study.
    Bunn PA; Kelly KL
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):54-8; discussion 59-60. PubMed ID: 7481862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.
    Hainsworth JD; Gray JR; Stroup SL; Kalman LA; Patten JE; Hopkins LG; Thomas M; Greco FA
    J Clin Oncol; 1997 Dec; 15(12):3464-70. PubMed ID: 9396399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.
    Kelly K; Lovato L; Bunn PA; Livingston RB; Zangmeister J; Taylor SA; Roychowdhury D; Crowley JJ; Gandara DR;
    Clin Cancer Res; 2001 Aug; 7(8):2325-9. PubMed ID: 11489808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.